| Literature DB >> 33287774 |
Anna Muzalyova1, Jens O Brunner2.
Abstract
BACKGROUND: The quality of life of chronically ill individuals, such as hay fever sufferers, is significantly dependent on their health behavior. This survey aimed to explain the health-related behavior of allergic individuals using the protection motivation theory (PMT) and the transtheoretical model (TTM).Entities:
Keywords: Hay fever management; Protection motivation theory; Threat appraisal; Transtheoretical model; Utilization of health measures
Mesh:
Substances:
Year: 2020 PMID: 33287774 PMCID: PMC7720499 DOI: 10.1186/s12889-020-09959-w
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Utilization of different allergy management measures expressed as TTM stages (in %)
| Early-stage (not taking action) | Late-stage (taking action) | ||||||
|---|---|---|---|---|---|---|---|
| Pre-contemplation | Contemplation | Preparation | Action | Maintenance | |||
| Medical supervision | 30.48 | 22.82 | 6.42 | 7.13 | 33.15 | ||
| Self-management | 18.18 | 7.49 | 2.50 | 12.48 | 59.35 | ||
| Anti-allergic medication | 10.70 | 7.13 | 1.43 | 13.19 | 67.55 | ||
| Specific immunotherapy | 37.62 | 27.09 | 5.17 | 4.81 | 25.31 | ||
| Allergen avoidance | 21.21 | 11.41 | 4.28 | 13.73 | 49.37 | ||
Results of the parallel analysis
| Parallel analysis | Explorative factor analysis | ||||
|---|---|---|---|---|---|
| Factor | Means | Percentile | Eigenvalue | Explained variance (%) | Cumulated variance (%) |
| 1 | 1.485 | 1.534 | 5.979 | 18.119 | 18.119 |
| 2 | 1.422 | 1.459 | 4.876 | 14.776 | 32.895 |
| 3 | 1.373 | 1.411 | 2.153 | 6.526 | 39.420 |
| 4 | 1.336 | 1.370 | 1.593 | 4.829 | 44.249 |
| 5 | 1.296 | 1.332 | 1.369 | 4.148 | 48.397 |
| 6 | 1.266 | 1.291 | 1.314 | 3.982 | 52.379 |
| 7 | 1.235 | 1.258 | 1.112 | 3.371 | 55.751 |
Rotated factor loading matrix (oblimin rotation)
| Factors | ||||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| | ||||||
| Hay fever is a disease | 0.179 | − 0.0180 | 0.116 | − 0.022 | 0.012 | |
| Hay fever is a chronic health condition [Ex] | 0.208 | 0.055 | 0.213 | −0.073 | 0.180 | |
| Hay fever is a serious health condition | 0.421 | 0.132 | 0.116 | − 0.064 | 0.183 | |
| Hay fever is a health condition that has to be treated [Ex] | 0.355 | 0.208 | 0.023 | 0.030 | 0.358 | |
| I see my hay fever as a long-term health condition | 0.389 | 0.099 | 0.142 | 0.011 | 0.007 | |
| Hay fever influences an individual’s well-being [Ex] | 0.198 | 0.176 | −0.007 | −0.041 | 0.006 | |
| | ||||||
| …I feel physically burdened | 0.066 | 0.225 | 0.325 | −0.089 | 0.070 | |
| …I feel limited in my social life | −0.018 | 0.256 | 0.387 | −0.115 | 0.059 | |
| …I feel limited in my spare time | −0.011 | 0.217 | 0.335 | −0.077 | 0.024 | |
| …my sleep quality is burdened | −0.014 | 0.233 | 0.262 | −0.219 | 0.061 | |
| …my overall well-being is burdened | −0.006 | 0.146 | 0.304 | −0.097 | 0.075 | |
| …I experience a loss of productivity | 0.085 | 0.082 | 0.288 | −0.051 | 0.066 | |
| | ||||||
| …weakens symptom severity | −0.032 | −0.203 | − 0.056 | 0.341 | 0.175 | |
| …helps better control allergic symptoms | −0.034 | −0.029 | 0.283 | 0.083 | 0.261 | |
| …helps manage everyday routines | 0.052 | −0.111 | 0.222 | 0.252 | 0.190 | |
| …improve overall well-being | 0.017 | −0.249 | 0.001 | 0.291 | 0.232 | |
| …helps staying productive during the pollen season [Ex] | 0.041 | −0.180 | 0.083 | 0.337 | 0.168 | |
| | ||||||
| …is time consuming | 0.036 | −0.016 | 0.150 | −0.122 | −0.030 | |
| …is impairing my everyday life | 0.273 | −0.274 | 0.101 | −0.176 | −0.172 | |
| …requires substantial financial effort | 0.323 | −0.101 | 0.167 | −0.201 | −0.076 | |
| …is annoying | 0.172 | −0.296 | 0.014 | −0.105 | −0.164 | |
| …is inconvenient | 0.163 | −0.215 | 0.143 | −0.118 | −0.209 | |
| …is not worth it [Ex] | 0.167 | −0.586 | 0.007 | −0.433 | −0.169 | |
| | ||||||
| Overall, I am capable of undertaking allergy management measures | −0.102 | 0.308 | −0.030 | 0.017 | 0.245 | |
| If required, I am capable of taking allergy management measures consistently | 0.233 | 0.288 | 0.015 | 0.162 | 0.119 | |
| If required, I am capable of taking allergy management measures regularly | −0.169 | 0.214 | −0.214 | − 0.139 | 0.144 | |
| If required, I am capable of taking allergy management measures despite difficulties [Ex] | −0.229 | 0.457 | −0.327 | −0.140 | 0.087 | |
| I can affect my health-related well-being during the pollen season | −0.231 | 0.202 | −0.224 | −0.047 | 0.016 | |
| My health-related well-being during the pollen season is dependent on my health behavior [Ex] | 0.099 | 0.217 | −0.181 | 0.048 | 0.013 | |
| If I take care of my allergy management during the pollen season, I can avoid severe allergic symptom [Ex] | 0.025 | 0.276 | −0.016 | 0.174 | 0.282 | |
| Proper allergy management requires me to change my habits, which is difficult for me [Ex] [R] | 0.146 | 0.162 | −0.043 | 0.181 | 0.140 | |
| My health-related well-being during the pollen season is dependent exclusively on factors I cannot control [Ex][R] | −0.213 | 0.108 | −0.472 | −0.136 | 0.056 | |
| If required, I can overcome inconveniences and difficulties related to allergy management during the pollen season [Ex] | −0.253 | 0.274 | −0.320 | −0.033 | 0.219 | |
Note. [Ex] denotes items that were excluded from use in the scales due to their low factor loadings or cross-construct loadings. [R] indicates reverse coded items
Correlations and square roots of average variance extracted
| (1) | (2) | (3) | (4) | (5) | |
|---|---|---|---|---|---|
| (1) Seriousness | |||||
| (2) Severity | 0.633 | ||||
| (3) Response efficacy | 0.184 | 0.025 | |||
| (4) Response costs | 0.148 | 0.310 | −0.345 | ||
| (5) Self-efficacy | −0.136 | −0.301 | 0.600 | −0.397 |
Association between the PMT constructs and examined allergy management measures
| Odds ratio (95% confidence interval) | |||||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
| Reference category (Yes a) | |||||
| Seriousness | 2.12 (1.56–2.89)** | 1.04 (0.77–1.41) | 0.95 (0.65–1.40) | 1.13 (0.81–1.56) | 0.72 (0.54–0.96)*† |
| Severity | 1.35 (1.02–1.81)* | 1.60 (1.21–2.11)** | 1.65 (1.16–2.35)** | 0.83 (0.61–1.13) | 2.12 (1.60–2.81)** |
| Response efficacy | 1.16 (0.83–1.62) | 1.00 (0.73–1.38) | 1.40 (0.96–2.06) | 1.08 (0.78–1.58) | 1.04 (0.77–1.42) |
| Response costs | 1.34 (1.03–1.73) | 0.88 (0.67–1.13) | 1.09 (0.79–1.51) | 1.25 (0.95–1.64) | 1.28 (1.00–1.64) |
| Self-efficacy | 4.52 (3.11–6.56)** | 1.37 (0.99–1.90)* | 1.52 (1.01–2.28)* | 0.97 (0.67–1.32) | 1.46 (1.07–1.99)*† |
| Allergy experience | 1.00 (0.98–1.03) | 1.02 (1.00–1.04) | 1.04 (1.00–1.07)*† | 1.00 (0.98–1.03) | 1.01 (0.99–1.03) |
| Gender (female) | 1.17 (0.79–1.63) | 1.44 (1.25–2.26)*† | 1.25 (0.96–2.17) | 0.70 (0.45–1.11) | 1.03 (0.81–1.69) |
| Medical supervision a | 0.39 (0.25–0.86)** | 2.22 (1.48–3.35)* | 9.80 (8.16–13.80)** | 0.66 (0.44–1.09) | |
| Self-management a | 4.76 (2.67–7.49)** | 0.91 (0.59–1.51) | 2.56 (1.87–3.52)** | ||
| Anti-allergic medication a | 1.26 (0.66–2.40) | 1.17 (0.67–1.87) | |||
| Specific immunotherapy a | 1.09 (0.67–1.78) | ||||
*Significance level p < 0.05, ** Significance level p < 0.01, † not significant due to multiple testing, a Reference category “taking action”
Model 1: R2 = 0.29 (Cox & Snell), 0.37 (Nagelkerke), χ2 (7) 169.74, p < 0.00; Model 2: R2 = 0.25 (Cox & Snell), 0.33 (Nagelkerke), χ2 (8) 168.24, p < 0.00; Model 3: R2 = 0.47 (Cox & Snell), 0.62 (Nagelkerke), χ2 (9) 347.43, p < 0.00; Model 4: R2 = 0.37 (Cox & Snell), 0.49 (Nagelkerke), χ2 (10) 250.47, p < 0.00; Model 5: R2 = 0.21 (Cox & Snell), 0.28 (Nagelkerke), χ2 (11) 121.75, p < 0.00